

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1644PNH

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Feb 24	PCTGEN now available on STN
NEWS	4	Feb 24	TEMA now available on STN
NEWS	5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	6	Feb 26	PCTFULL now contains images
NEWS	7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	8	Mar 24	PATDPAFULL now available on STN
NEWS	9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	10	Apr 11	Display formats in DGENE enhanced
NEWS	11	Apr 14	MEDLINE Reload
NEWS	12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	13	AUG 15	Indexing from 1937 to 1946 added to records in CA/CAPLUS
NEWS	14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	15	Apr 28	RDISCLOSURE now available on STN
NEWS	16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	19	May 19	Simultaneous left and right truncation added to WSCA
NEWS	20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS	21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS	22	Jun 06	PASCAL enhanced with additional data
NEWS	23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS	24	Jun 25	HSDB has been reloaded
NEWS	25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS	26	Jul 21	Identification of STN records implemented
NEWS	27	Jul 21	Polymer class term count added to REGISTRY
NEWS	28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS	29	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	30	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	31	AUG 15	PATDPAFULL: one FREE connect hour, per account, in September 2003
NEWS	32	AUG 15	PCTGEN: one FREE connect hour, per account, in September 2003
NEWS	33	AUG 15	RDISCLOSURE: one FREE connect hour, per account, in September 2003
NEWS	34	AUG 15	TEMA: one FREE connect hour, per account, in September 2003
NEWS	35	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	36	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS	37	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Right Truncation
NEWS	38	AUG 18	Simultaneous left and right truncation added to ANABSTR

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
 MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
 AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:34:11 ON 19 AUG 2003

=> file medline embase biosis scisearch caplus		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 18:34:23 ON 19 AUG 2003

FILE 'EMBASE' ENTERED AT 18:34:23 ON 19 AUG 2003
 COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 18:34:23 ON 19 AUG 2003
 COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'SCISEARCH' ENTERED AT 18:34:23 ON 19 AUG 2003
 COPYRIGHT 2003 THOMSON ISI

FILE 'CAPLUS' ENTERED AT 18:34:23 ON 19 AUG 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s antibod?
 L1 2461286 ANTIBOD?

=> s l1 and neutraliz?
 L2 116085 L1 AND NEUTRALIZ?

=> sl2 and Nitrosylated cysteine
 SL2 IS NOT A RECOGNIZED COMMAND
 The previous command name entered was not recognized by the system.
 For a list of commands available to you in the current file, enter
 "HELP COMMANDS" at an arrow prompt (=>).

=> s l2 and cysteine
 L3 876 L2 AND CYSTEINE

=> s l3 and nitrosylated
 L4 4 L3 AND NITROSYLATED

=> dup remove l4
 PROCESSING COMPLETED FOR L4
 L5 2 DUP REMOVE L4 (2 DUPLICATES REMOVED)

=> d 15 1-2 cbib abs

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
1998:485093 Document No. 129:121648 **Antibodies** specifically recognizing a **nitrosylated** protein, method of preparation, and therapeutic and diagnostic use. Chagnaud, Jean-Luc; Geffard, Michel; Veyret, Bernard; Vincendeau, Philippe (Centre National de la Recherche Scientifique (CNRS), Fr.). PCT Int. Appl. WO 9829452 A1 19980709, 143 pp. DESIGNATED STATES: W: JP, US; RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (French). CODEN: PIXXD2. APPLICATION: WO 1997-FR2412 19971223. PRIORITY: FR 1996-16207 19961230.

AB Polyclonal and monoclonal **antibodies** are provided which specifically recognize a **nitrosylated** protein, and, more particularly, a NO carrier, e.g. albumin. Also provided are immunogens for prep. the **antibodies** and the pharmaceutical compns. contg. them. Further provided is a method using the **antibodies** for detecting in vitro **nitrosylated** proteins in a biol. sample.

L5 ANSWER 2 OF 2 MEDLINE on STN DUPLICATE 1
97131703 Document Number: 97131703. PubMed ID: 8977204. Albumin **nitrosylated** by activated macrophages possesses antiparasitic effects **neutralized** by anti-NO-acetylated-**cysteine antibodies**. Mnaimneh S; Geffard M; Veyret B; Vincendeau P. (Parasitology Laboratory, University of Bordeaux II, France.) JOURNAL OF IMMUNOLOGY, (1997 Jan 1) 158 (1) 308-14. Journal code: 2985117R. ISSN: 0022-1767. Pub. country: United States. Language: English.

AB Activated macrophages exert an L-arginine-dependent cytostatic effect on the extracellular parasite, Trypanosoma musculi. This effect is not observed in the absence of albumin in the culture medium but is restored by the addition of albumin, indicating the presence of an albumin-nitric oxide (NO) adduct acting as an effector molecule. Since L-**cysteine** represents a privileged target for NO, an immunochemical approach was performed using an acetylated-**cysteine**-BSA conjugate. This conjugate was **nitrosylated** using sodium nitrite as a NO donor. Binding of NO to the conjugated haptens was assayed using spectrophotometry. It was completely abolished by mercuric chloride, confirming the presence of an S-NO bond. Polyclonal Abs were obtained after immunizing rabbits with S-nitroso-acetylated-**cysteine** (NO-ac-Cys) conjugates. Using the enzyme-linked immunosorbent assay method, Ab avidity and specificity were determined by competition experiments between NO-ac-Cys-conjugated compounds and other **nitrosylated** or non-**nitrosylated** compounds. The resulting cross-reactivity ratios showed that conjugated NO-ac-Cys-BSA was the best recognized compound. These Ab were used for an in vitro study of the kinetics of NO-derived compounds from activated murine macrophages. Anti-NO-ac-Cys Ab inhibited the antimicrobial effect of activated macrophages on the extracellular parasite, T. musculi. Moreover, the L-arginine-dependent antiparasitic activity of supernatants from Calmette-Guerin bacillus-activated macrophages required the presence of albumin and was also inhibited by anti-NO-ac-Cys Ab, showing the effector role of S-nitroso-albumin.

=> dup remove l3

PROCESSING COMPLETED FOR L3

L6 355 DUP REMOVE L3 (521 DUPLICATES REMOVED)

=> s l6 and nitrosylated

L7 2 L6 AND NITROSYLATED

=> dup remove l7

PROCESSING COMPLETED FOR L7

L8 2 DUP REMOVE L7 (0 DUPLICATES REMOVED)

=> d 18 1-2 cbib abs

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

1998:485093 Document No. 129:121648 **Antibodies** specifically recognizing a **nitrosylated** protein, method of preparation, and therapeutic and diagnostic use. Chagnaud, Jean-Luc; Geffard, Michel; Veyret, Bernard; Vincendeau, Philippe (Centre National de la Recherche Scientifique (CNRS), Fr.). PCT Int. Appl. WO 9829452 A1 19980709, 143 pp. DESIGNATED STATES: W: JP, US; RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (French). CODEN: PIXXD2. APPLICATION: WO 1997-FR2412 19971223. PRIORITY: FR 1996-16207 19961230.

AB Polyclonal and monoclonal **antibodies** are provided which specifically recognize a **nitrosylated** protein, and, more particularly, a NO carrier, e.g. albumin. Also provided are immunogens for prepg. the **antibodies** and the pharmaceutical compns. contg. them. Further provided is a method using the **antibodies** for detecting in vitro **nitrosylated** proteins in a biol. sample.

L8 ANSWER 2 OF 2 MEDLINE on STN

97131703 Document Number: 97131703. PubMed ID: 8977204. Albumin **nitrosylated** by activated macrophages possesses antiparasitic effects **neutralized** by anti-NO-acetylated-**cysteine antibodies**. Mnaimneh S; Geffard M; Veyret B; Vincendeau P. (Parasitology Laboratory, University of Bordeaux II, France.) JOURNAL OF IMMUNOLOGY, (1997 Jan 1) 158 (1) 308-14. Journal code: 2985117R. ISSN: 0022-1767. Pub. country: United States. Language: English.

AB Activated macrophages exert an L-arginine-dependent cytostatic effect on the extracellular parasite, Trypanosoma musculi. This effect is not observed in the absence of albumin in the culture medium but is restored by the addition of albumin, indicating the presence of an albumin-nitric oxide (NO) adduct acting as an effector molecule. Since L-**cysteine** represents a privileged target for NO, an immunochemical approach was performed using an acetylated-**cysteine**-BSA conjugate. This conjugate was **nitrosylated** using sodium nitrite as a NO donor. Binding of NO to the conjugated haptens was assayed using spectrophotometry. It was completely abolished by mercuric chloride, confirming the presence of an S-NO bond. Polyclonal Abs were obtained after immunizing rabbits with S-nitroso-acetylated-**cysteine** (NO-ac-Cys) conjugates. Using the enzyme-linked immunosorbent assay method, Ab avidity and specificity were determined by competition experiments between NO-ac-Cys-conjugated compounds and other **nitrosylated** or non-**nitrosylated** compounds. The resulting cross-reactivity ratios showed that conjugated NO-ac-Cys-BSA was the best recognized compound. These Ab were used for an in vitro study of the kinetics of NO-derived compounds from activated murine macrophages. Anti-NO-ac-Cys Ab inhibited the antimicrobial effect of activated macrophages on the extracellular parasite, T. musculi. Moreover, the L-arginine-dependent antiparasitic activity of supernatants from Calmette-Guerin bacillus-activated macrophages required the presence of albumin and was also inhibited by anti-NO-ac-Cys Ab, showing the effector role of S-nitroso-albumin.

=> s 16 and cysteine conjugated glutaldehyde

L9 0 L6 AND CYSTEINE CONJUGATED GLUTALDEHYDE

=> s 16 and "anti-NO-glu-Cys"

L10 0 L6 AND "ANTI-NO-GLU-CYS"

=> s 16 and anti-NO

L11 1 L6 AND ANTI-NO

=> d 111 cbib abs

L11 ANSWER 1 OF 1 MEDLINE on STN

97131703 Document Number: 97131703. PubMed ID: 8977204. Albumin nitrosylated by activated macrophages possesses antiparasitic effects **neutralized by anti-NO-acetylated-cysteine antibodies**. Mnaimneh S; Geffard M; Veyret B; Vincendeau P. (Parasitology Laboratory, University of Bordeaux II, France.) JOURNAL OF IMMUNOLOGY, (1997 Jan 1) 158 (1) 308-14. Journal code: 2985117R. ISSN: 0022-1767. Pub. country: United States. Language: English.

AB Activated macrophages exert an L-arginine-dependent cytostatic effect on the extracellular parasite, *Trypanosoma muscili*. This effect is not observed in the absence of albumin in the culture medium but is restored by the addition of albumin, indicating the presence of an albumin-nitric oxide (NO) adduct acting as an effector molecule. Since L-**cysteine** represents a privileged target for NO, an immunochemical approach was performed using an acetylated-**cysteine**-BSA conjugate. This conjugate was nitrosylated using sodium nitrite as a NO donor. Binding of NO to the conjugated haptens was assayed using spectrophotometry. It was completely abolished by mercuric chloride, confirming the presence of an S-NO bond. Polyclonal Abs were obtained after immunizing rabbits with S-nitroso-acetylated-**cysteine** (NO-ac-Cys) conjugates. Using the enzyme-linked immunosorbent assay method, Ab avidity and specificity were determined by competition experiments between NO-ac-Cys-conjugated compounds and other nitrosylated or non-nitrosylated compounds. The resulting cross-reactivity ratios showed that conjugated NO-ac-Cys-BSA was the best recognized compound. These Ab were used for an in vitro study of the kinetics of NO-derived compounds from activated murine macrophages. **Anti-NO**-ac-Cys Ab inhibited the antimicrobial effect of activated macrophages on the extracellular parasite, *T. muscili*. Moreover, the L-arginine-dependent antiparasitic activity of supernatants from Calmette-Guerin bacillus-activated macrophages required the presence of albumin and was also inhibited by **anti-NO**-ac-Cys Ab, showing the effector role of S-nitroso-albumin.

=> d 16

L6 ANSWER 1 OF 355 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2003:511361 CAPLUS
 DN 139:67772
 TI Mutein of Tat protein of human immunodeficiency virus
 IN Klein, Michel; Rappaport, Jay; Zagury, Jean-Francois
 PA Aventis Pasteur, Fr.
 SO PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003054006	A2	20030703	WO 2002-EP14841	20021204
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2001-339607P	P	20011211		

=> s nitrosylated protein
 L12 117 NITROSYLATED PROTEIN

=> s l12 and antibod?
L13 8 L12 AND ANTIBOD?

=> dup remove l13
PROCESSING COMPLETED FOR L13
L14 4 DUP REMOVE L13 (4 DUPLICATES REMOVED)

=> d l14 1-4 cbib abs

L14 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
2002:368771 Document No. 136:366141 Method for assaying protein
nitrosylation. Jaffrey, Samie; Ferris, Christopher D.; Snyder, Solomon H.
(The Johns Hopkins University, USA; Memorial Sloan-Kettering Cancer
Center). PCT Int. Appl. WO 2002039119 A2 20020516, 39 pp. DESIGNATED
STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI,
CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL,
PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO
2001-US42826 20011029. PRIORITY: US 2000-PV244097 20001027.

AB Many of the effects of nitric oxide are mediated by the direct
modification of cysteine residues resulting in an adduct called a
nitrosothiol. A method to detect proteins which contain nitrosothiols
involves several steps. Nitrosylated cysteines are converted to tagged
cysteines. Tagged proteins can then be detected, for example, by
immunoblotting and/or can be purified by affinity chromatog. The method
is applicable to the detection of **S-nitrosylated**
proteins in cell lysates following in vitro S-nitrosylation, as
well as to the detection of endogenous S-nitrosothiols in selected protein
substrates.

L14 ANSWER 2 OF 4 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
2001:400866 Document No.: PREV200100400866. Increased levels of
nitrosylated proteins in serum and DNA damage in
lymphocytes of patients undergoing hemodialysis. Mitrogianni, Z. (1);
Barbouti, A.; Galaris, D.; Siamopoulos, K. C. (1). (1) Dept. of
Nephrology, University Hospital of Ioannina, Ioannina Greece. Nephrology
Dialysis Transplantation, (June, 2001) Vol. 16, No. 6, pp. A139. print.
Meeting Info.: Annual Congress of the European Renal Association and the
European Dialysis and Transplant Association Vienna, Austria June 24-27,
2001 ISSN: 0931-0509. Language: English. Summary Language: English.

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
1998:485093 Document No. 129:121648 **Antibodies** specifically
recognizing a **nitrosylated protein**, method of
preparation, and therapeutic and diagnostic use. Chagnaud, Jean-Luc;
Geffard, Michel; Veyret, Bernard; Vincendeau, Philippe (Centre National de
la Recherche Scientifique (CNRS), Fr.). PCT Int. Appl. WO 9829452 A1
19980709, 143 pp. DESIGNATED STATES: W: JP, US; RW: AT, BE, CH, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (French). CODEN: PIXXD2.
APPLICATION: WO 1997-FR2412 19971223. PRIORITY: FR 1996-16207 19961230.

AB Polyclonal and monoclonal **antibodies** are provided which
specifically recognize a **nitrosylated protein**, and,
more particularly, a NO carrier, e.g. albumin. Also provided are
immunogens for prep. the **antibodies** and the pharmaceutical
compsns. contg. them. Further provided is a method using the
antibodies for detecting in vitro **nitrosylated**
proteins in a biol. sample.

L14 ANSWER 4 OF 4 MEDLINE on STN DUPLICATE 1
1998019329 Document Number: 98019329. PubMed ID: 9353418. Nitrosylated

bovine serum albumin derivatives as pharmacologically active nitric oxide congeners. Ewing J F; Young D V; Janero D R; Garvey D S; Grinnell T A. (NitroMed, Inc., Bedford, Massachusetts 01730, USA.) JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (1997 Nov) 283 (2) 947-54. Journal code: 0376362. ISSN: 0022-3565. Pub. country: United States. Language: English.

AB Although nitrosothiols have been suggested to act as regulators of cell (patho)physiology, little is known about the pharmacology of **nitrosylated proteins** as nitric oxide (NO.) congeners. We describe the molecular consequences of nitrosylating bovine serum albumin (BSA) at multiple specific sites and demonstrate that the product S-nitroso proteins exert NO.-like activity. The content of nucleophilic nitrosylation sites (i.e., free sulfhydryl groups) in native BSA was increased by either reduction with dithiothreitol or thiolation with N-acetylhomocysteine. Fourteen moles of nitrogen monoxide (NO)/mol BSA equivalent were then selectively positioned on either the endogenous sulfhydryl groups of reduced BSA or the homocysteine moieties of thiolated BSA, respectively. Each resulting S-nitroso protein adduct was an oligomeric mixture across the >2000 kDa to approximately 66 kDa molecular mass range. The BSA-derived S-nitroso proteins were immunoreactive with **antibodies** against native BSA but evidenced compromised long-chain fatty acid binding. Both types of BSA-derived S-nitroso proteins suppressed human coronary artery smooth muscle cell proliferation to a similar degree (IC50 approximately 70 microM NO. equivalents) and were significantly more effective antiproliferative agents than a standard NO. donor, DETA NONOate. Antiproliferative bioactivity reflected the NO functionalities carried by each protein, but was independent of molecular mass of the nitrosylated BSA adducts. These data exemplify the rational design and characterization of protein-based S-nitrosothiols as NO. congeners and suggest that such agents could have therapeutic potential as NO delivery systems.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	52.40	52.61
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.60	-2.60

STN INTERNATIONAL LOGOFF AT 18:42:10 ON 19 AUG 2003